Bod Science Sees Cash Flow Changes Amid Biortica Deal

Bod Australia Ltd (AU:BOD) has released an update.

Bod Science Limited, a cannabis-focused drug development company, reported a significant decrease in net cash outflow to $4k for Q1 FY2025, aided by funding from Biortica Agrimed Limited. The company’s quarterly customer receipts rose by 176% from the previous quarter, although they were down 70% compared to the same period last year. The company is navigating through a Deed of Company Arrangement and working towards shareholder approval for a Share Purchase Agreement with Biortica.

For further insights into AU:BOD stock, check out TipRanks’ Stock Analysis page.